Antihyperlipidemic Effects of Rhapontin and Rhapontigenin from *Rheum undulatum* in Rats Fed a High-Cholesterol Diet

### Abstract

Rhapontin was purified from a methanol extract from the roots of *Rheum undulatum*, and rhapontigenin was produced by an enzymatic transformation of rhapontin. Rats were fed a high-cholesterol diet to induce hyperlipidemia, followed by oral treatment with rhapontin or rhapontigenin (1–5 mg/kg/day). Rhapontin and rhapontigenin treatment resulted in a significant (p < 0.05) dose-dependent decrease in the serum lipid level, while the high-density lipoprotein cholesterol level increased slightly compared with the experimental control. Furthermore, rhapontin and rhapontigenin treatment improved the pathological characteristics of the degenerating fatty liver in high-cholesterol diet-induced hyperlipidemic rats dose-dependently. Aspartate aminotransferase and alanine aminotransferase levels in rhapontin- and rhapontigenin-treated hyperlipidemic rats were not significantly different from those in the control. These results indicate that rhapontin and rhapontigenin can be used as potential antihyperlipidemic agents.

### Abbreviations

- ALT: alanine aminotransferase
- AST: aspartate aminotransferase
- HCD: high-cholesterol diet
- HDL-C: high-density lipoprotein cholesterol
- HE: hematoxylin and eosin
- LDL-C: low-density lipoprotein cholesterol
- RHA: rhapontin
- RHG: rhapontigenin
- TC: total cholesterol
- TG: triglyceride
- VLDL-C: very low-density lipoprotein cholesterol

### Supporting information

Available online at [http://www.thieme-connect.de/products](http://www.thieme-connect.de/products)

### Introduction

Hyperlipidemia, an increase in the blood lipid level, is the leading cause of cardiovascular disease and death worldwide. Reducing the LDL-C level in individuals with hyperlipidemia decreases the risk of cardiovascular disease [1]. By contrast, HDL-C lowers the risk of cardiovascular diseases by reversing cholesterol transport, inhibiting LDL-C oxidation, and decreasing platelet aggregability [2,3]. Statins are widely prescribed as lipid lowering agents; however, they can elicit serious side effects such as myopathy and hepatocytotoxicity [4,5]. Therefore, the development of new agents for lowering blood lipid levels is needed.

Stilbenes are well-studied compounds that possess anticancer, antioxidative, and anti-inflammatory activities [6–8], and methoxylated stilbenes enhance those bioactivities [9,10]. Rhapontigenin (3,3',5-trihydroxy-4'-methoxystilbene) is an aglycone of rhapontin (3,3',5-trihydroxy-4'-methoxystilbene-3-O-glucoside), which is isolated from the roots of *Rheum undulatum* L, from the family Polygonaceae (Fig. 1) [11]. Rhapontigenin is a methoxylated stilbene with anticancer, antioxidative, and anti-inflammatory effects [12,13]. Rhapontigenin is much more potent than rhapontin in inhibiting thrombosis and allergic reactions [14]. To increase the bioactivity of rhapontin isolated from a methanol extract from the roots of *Rheum undulatum* [15,16], rhapontigenin is prepared from rhapontin by an enzymatic transformation [17]. In this study, RHA and RHG were investigated for their antihyperlipidemic activity, and the results were compared with simvastatin, a well-known hypolipidemic drug.

**Fig. 1**
Results and Discussion

RHA, RHG, or simvastatin (positive control) was orally administered to HCD-fed rats for four weeks (Table 1S, Supporting Information). The percent changes (Δ%) in body weight were not significantly reduced except in HCD-fed rats treated with RHG at 5 mg/kg/day (Table 1). The Δ% body weight significantly (p < 0.05) decreased in HCD-fed rats treated with RHG at 5 mg/kg/day compared with the HCD-fed control. The relative liver weight increased in HCD-fed rats compared with the water-treated control; however, it decreased in HCD-fed rats treated with RHA and RHG compared with rats fed the normal diet. Daily food consumption was similar in all groups, indicating that the test compounds did not suppress appetite. To investigate the antihyperlipidemic effect of RHA and RHG, the serum lipid level was measured in HCD-induced hyperlipidemic rats. The percent changes (Δ%) in body weight were not significantly reduced except in HCD-fed rats treated with RHG at 5 mg/kg/day (Table 1). The Δ% body weight significantly (p < 0.05) decreased in HCD-fed rats treated with RHG at 5 mg/kg/day compared with the HCD-fed control. The relative liver weight increased in HCD-fed rats compared with the water-treated control; however, it decreased in HCD-fed rats treated with RHA and RHG compared with rats fed the normal diet. Daily food consumption was similar in all groups, indicating that the test compounds did not suppress appetite.

RHA, RHG, or simvastatin (positive control) was orally administered to HCD-fed rats for four weeks (Table 1S, Supporting Information). The percent changes (Δ%) in body weight were not significantly reduced except in HCD-fed rats treated with RHG at 5 mg/kg/day (Table 1). The Δ% body weight significantly (p < 0.05) decreased in HCD-fed rats treated with RHG at 5 mg/kg/day compared with the HCD-fed control. The relative liver weight increased in HCD-fed rats compared with the water-treated control; however, it decreased in HCD-fed rats treated with RHA and RHG compared with rats fed the normal diet. Daily food consumption was similar in all groups, indicating that the test compounds did not suppress appetite.

To investigate the antihyperlipidemic effect of RHA and RHG, the serum lipid level was measured in HCD-induced hyperlipidemic rats. The percent changes (Δ%) in body weight were not significantly reduced except in HCD-fed rats treated with RHG at 5 mg/kg/day (Table 1). The Δ% body weight significantly (p < 0.05) decreased in HCD-fed rats treated with RHG at 5 mg/kg/day compared with the HCD-fed control. The relative liver weight increased in HCD-fed rats compared with the water-treated control; however, it decreased in HCD-fed rats treated with RHA and RHG compared with rats fed the normal diet. Daily food consumption was similar in all groups, indicating that the test compounds did not suppress appetite.

Table 1

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>% ΔWeight on day 28</th>
<th>Relative liver weight</th>
<th>Average daily diet consumption (g/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>141.7 ± 14.5&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>2.8 ± 0.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>15.3 ± 1.4</td>
</tr>
<tr>
<td>II</td>
<td>155.8 ± 17.0&lt;sup&gt;b&lt;/sup&gt;</td>
<td>4.4 ± 0.8&lt;sup&gt;d&lt;/sup&gt;</td>
<td>15.9 ± 2.9</td>
</tr>
<tr>
<td>III</td>
<td>147.4 ± 14.8&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>4.0 ± 0.7&lt;sup&gt;d&lt;/sup&gt;</td>
<td>15.5 ± 2.6</td>
</tr>
<tr>
<td>IV</td>
<td>143.4 ± 10.7&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>3.7 ± 0.3&lt;sup&gt;b,c,d&lt;/sup&gt;</td>
<td>17.2 ± 3.1</td>
</tr>
<tr>
<td>V</td>
<td>148.8 ± 9.3&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>4.2 ± 0.4&lt;sup&gt;c,d&lt;/sup&gt;</td>
<td>16.0 ± 2.8</td>
</tr>
<tr>
<td>VI</td>
<td>143.4 ± 12.0&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>4.1 ± 0.4&lt;sup&gt;d&lt;/sup&gt;</td>
<td>17.2 ± 2.5</td>
</tr>
<tr>
<td>VII</td>
<td>137.9 ± 6.5&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>3.9 ± 0.4&lt;sup&gt;c&lt;/sup&gt;</td>
<td>15.7 ± 2.7</td>
</tr>
<tr>
<td>VIII</td>
<td>143.1 ± 21.1&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>3.5 ± 0.3&lt;sup&gt;d&lt;/sup&gt;</td>
<td>16.5 ± 2.8</td>
</tr>
<tr>
<td>IX</td>
<td>130.5 ± 7.5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>3.9 ± 0.65&lt;sup&gt;c,d&lt;/sup&gt;</td>
<td>16.5 ± 2.1</td>
</tr>
</tbody>
</table>

Group I, normal diet + 10 mL/kg/day distilled water; group II, HCD; group III, HCD + 1 mg/kg/day simvastatin; group IV, HCD + 1 mg/kg/day RHA; group V, HCD + 2.5 mg/kg/day RHA; group VI, HCD + 5 mg/kg/day RHA; group VII, HCD + 1 mg/kg/day RHG; group VIII, HCD + 2.5 mg/kg/day RHG; and group IX, HCD + 5 mg/kg/day RHG; a, b, c, d Means in the same column not sharing a common superscript are significantly (p < 0.05) different between groups.
studies are needed to clarify the mechanism of action of RHG on antihyperlipidemia. The liver from HCD-fed rats treated with RHA or RHG was examined for histopathological changes. Liver cells from HCD-fed rats were altered compared with those of rats fed a normal diet, which did not show abnormal morphology (Fig. 2). Numerous lipid droplets were observed in the cytoplasm of centrilobular hepatocytes in livers from HCD-fed rats compared with those from rats fed a normal diet (Fig. 2A and B). By contrast, the number of lipid droplets significantly decreased in HCD-fed rats treated with simvastatin (Fig. 2C), RHA, or RHG, dose-dependently (Fig. 2D–I). Lipid droplets in liver cells from HCD-fed rats treated with RHA or RHG at 5 mg/kg/day were hardly observed (Fig. 2F and I). The results indicate that methoxylated stilbenes, especially RHG, can reverse HCD-induced liver cell degeneration.

In conclusion, RHA and RHG treatment lowered the serum lipid level dose-dependently and reversed hyperlipidemia in HCD-fed rats. A histological study also showed that RHA and RHG decreased the number of lipid droplets in liver cells from HCD-fed rats, consistent with the serum lipid analysis results. RHG showed a higher preventive effect against hyperlipidemia than RHA, illustrating that the aglycone was more effective to reduce the risk for hyperlipidemia than the glycosylated counterpart.

### Materials and Methods

#### Chemicals

RHA (3,3′,5-trihydroxy-4′-methoxystilbene-3-O-glucoside) was isolated from a methanol extract of *Rheum undulatum* roots, and RHG (3,3′,5-trihydroxy-4′-methoxystilbene) was produced from RHA via an enzymatic transformation using Pectinex® (Novo-enzymes) as previously described [17]. The purity of RHA and RHG was over 95%. Simvastatin (purity ≥ 97%) and DMSO were purchased from Sigma Chemical Co.

### Table 2

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>U/L</th>
<th>Levels (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AST</td>
<td>ALT</td>
</tr>
<tr>
<td>I</td>
<td>86.7 ± 11.0</td>
<td>40.5 ± 8.1</td>
</tr>
<tr>
<td>II</td>
<td>92.5 ± 7.0</td>
<td>39.3 ± 4.3</td>
</tr>
<tr>
<td>III</td>
<td>101.3 ± 21.1</td>
<td>40.3 ± 3.8</td>
</tr>
<tr>
<td>IV</td>
<td>90.4 ± 6.8</td>
<td>42.5 ± 4.3</td>
</tr>
<tr>
<td>V</td>
<td>88.2 ± 12.4</td>
<td>38.0 ± 6.9</td>
</tr>
<tr>
<td>VI</td>
<td>85.8 ± 6.1</td>
<td>35.2 ± 3.6</td>
</tr>
<tr>
<td>VII</td>
<td>84.5 ± 6.9</td>
<td>41.2 ± 1.5</td>
</tr>
<tr>
<td>VIII</td>
<td>87.8 ± 7.0</td>
<td>39.5 ± 4.2</td>
</tr>
<tr>
<td>IX</td>
<td>89.0 ± 14.1</td>
<td>38.3 ± 5.3</td>
</tr>
</tbody>
</table>

Group I, normal diet + 10 mL/kg/day distilled water; group II, HCD; group III, HCD + 1 mg/kg/day simvastatin; group IV, HCD + 1 mg/kg/day RHA; group V, HCD + 2.5 mg/kg/day RHA; group VI, HCD + 5 mg/kg/day RHA; group VII, HCD + 1 mg/kg/day RHG; group VIII, HCD + 2.5 mg/kg/day RHG; and group IX, HCD + 5 mg/kg/day RHG. Means in the same column not sharing a common superscript are significantly (p < 0.05) different between groups.

Fig. 2 Histological analysis of the liver from hyperlipidemic rats who were fed a high-cholesterol diet and treated with rhapontin or rhapontigenin. A normal diet; B HCD; C HCD + 1 mg/kg/day simvastatin; D HCD + 1 mg/kg/day RHA; E HCD + 2.5 mg/kg/day RHA; F HCD + 5 mg/kg/day RHA; G HCD + 1 mg/kg/day RHG; H HCD + 2.5 mg/kg/day RHG; I HCD + 5 mg/kg/day RHG. All images are shown at 200× magnification. (Color figure available online only.)
Experimental animals and diets
Sprague Dawley rats (n = 54), five weeks old and weighing approximately 100–110 g, were purchased from Koatech. They received a normal diet for one week to allow for adaptation. Rats were housed in cages under strict standard conditions (22 ± 1 °C; 55 ± 5% humidity; 12-h light and 12-h dark cycles). The animals had free access to water and a normal diet or an experimental HCD purchased from Feedlab. The composition of diets is shown in Table 15, Supporting Information. All experimental procedures were approved by the Korea University Institutional Animal Care and Use Committee (approval No. KUIACUC-2012–100) and were followed according to the Guide for the Care and Use of Laboratory Animals (NIH publication No. 85–23, 1996).

Induction of hyperlipidemia with a high-cholesterol diet
After adaptation, rats were randomly divided into nine groups, with each group consisting of six rats. RHA or RHG was orally administered to rats daily for four weeks. Animals in group I (negative control) were fed a normal diet and orally treated with distilled water at 10 mL/kg/day for four weeks. Animals in group II (experimental control) were fed the HCD instead of the normal diet (Table 15, Supporting Information). Animals in group III (positive control) were fed the HCD and orally treated with simvastatin at 1 mg/kg/day in 10 mL/kg DMSO and distilled water (1:9, v/v) for four weeks. Animals in groups IV, V, and VI were fed the HCD and orally treated with RHA at 1, 2.5, and 5 mg/kg/day in 10 mL/kg DMSO and distilled water (1:9, v/v), respectively. Animals in groups VII, VIII, and IX were fed the HCD and orally treated with RHG at 1, 2.5, and 5 mg/kg/day in 10 mL/kg DMSO and distilled water (1:9, v/v), respectively.

Measurement of daily food intake, body weight, and relative liver weight
Daily food intake was assessed by subtracting the weight of any leftover food from the weight of the total amount of food provided, divided by six for each group. The body weight of each rat was obtained weekly. The absolute liver weight was obtained, and the relative liver weight per 100 g of total body weight was calculated as follows:

\[
\text{Rel. liver weight} = \frac{\text{weight of rat liver (g)}}{\text{body weight of the final experimental day (g)}} \times 100
\]

Blood collection and biochemical assays
After treatment for four weeks, blood was collected from the heart of overnight fasted rats under diethyl ether anesthesia and allowed to clot at room temperature. Sera were obtained by centrifugation at 10 000 × g at 4 °C for 20 min. Serum TG, TC, HDL-C, AST, and ALT levels were measured using the FUSI DRI-CHEM SLIDE kit and a FUSI DRI-CHEM 4000 analyzer (Fujifilm). The serum LDL-C level was calculated by applying Friedwann’s equation:

\[
\text{LDL-C} = [\text{TC} - (\text{HDL-C} + \frac{\text{TG}}{5})]
\]

The serum VLDL-C level was calculated by applying the following equation:

\[
\text{VLDL-C} = \frac{\text{TG}}{5}
\]

Hepatic morphology
For histological analysis, liver specimens were fixed in 10% formalin and embedded in paraffin. Paraffin blocks were cut at 5 µm, and sections were stained with hematoxylin and eosin and then mounted with Canada balsam. The slides were observed under an optical microscope at 200× magnification [22].

Statistical analysis
All data are presented as means ± standard error. The data were analyzed using the SPSS statistical analysis program. Significant differences between groups were determined by one-way analysis of variance. Post hoc Duncan’s multiple-range tests were performed when between-group differences were identified. Results were considered to be statistically significant at p < 0.05.

Supporting information
Details about the composition of the experimental diets are available as Supporting Information.

Acknowledgments
This research was supported by the High Value-added Food Technology Development Program, Ministry of Agriculture, Food and Rural Affairs, Republic of Korea.

Conflict of Interest
The authors declare no conflict of interest.

References
1 Sharma RK, Singh VN, Reddy HK. Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk. Vasc Health Risk Manag 2009; 5: 793–799
19 Chen Q, Wang E, Ma L, Zhai P. Dietary resveratrol increases the expression of hepatic 7alpha-hydroxylase and ameliorates hypercholesterolemia in high-fat fed C57BL/6J mice. Lipids Health Dis 2012; 11: 56